Bullous pemphigoid, an autoimmune blistering disease with protean clinical manifestations. Review of recent advances from the bench to the bedside

Giornale Italiano di Dermatologia e Venereologia

Volumn 141, Issue 6, 2006, Pages 495-505

  Lebeau, S ^a   Clivaz, L ^a   Fontao, L ^a   Borradori, L ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Bullous pemphigoid, diagnosis; Bullous pemphigoid, drug therapy; ELISA

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; BULLOUS PEMPHIGOID ANTIGEN 1; CHLORAMBUCIL; CLOBETASOL PROPIONATE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; PROTEIN BP180; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANTIGEN SPECIFICITY; AUTOIMMUNE DISEASE; BLISTER; BULLOUS PEMPHIGOID; CLINICAL FEATURE; DIABETES MELLITUS; DIAGNOSTIC PROCEDURE; ECZEMA; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HYPOTHALAMUS DISEASE; IMMUNOELECTRON MICROSCOPY; IMMUNOFLUORESCENCE MICROSCOPY; PATHOPHYSIOLOGY; PLASMAPHERESIS; PROGNOSIS; RASH; REVIEW; SKIN ATROPHY; SKIN INFECTION;

EID: 33847246863     PISSN: 03920488     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (87)

1. Lever WF. Pemphigus. Medicine 1953; 32:1-123.
2. Jordon RE, Beutner EH, Witebsky E, Blumental G, Hale WL, Lever WF. Basement zone antibodies in bullous pemphigoid. JAMA 1967;200:751-6.
3. Li KH, Sawamura D, Giudice GJ, Diaz LA, Mattel MG, Chu ML et al. Genomic organization of collagenous domains and chromosomal assignment of human 180-kDa bullous pemphigoid antigen-2, a novel collagen of stratified squamous epithelium. J Biol Chem 1991;266:24064-9.
4. Giudice GJ, Emery DJ, Diaz LA. Cloning and primary structural analysis of the bullous pemphigoid autoantigen BP180. J Invest Dermatol 1992;99:243-50.
5. Stanley JR, Tanaka T, Mueller S, Klaus-Kovtun V, Roop D. Isolation of complementary DNA for bullous pemphigoid antigen by use of patients' autoantibodies. J Clin Invest 1988;82:1864-70.
6. Labib RS, Anhalt GJ, Patel HP, Mutasirn DF, Diaz LA. Molecular heterogeneity of the bullous pemphigoid antigens as detected by immunoblotting. J Immunol 1986;136:1231-5.
7. Korman NJ. Bullous pemphigoid. The latest in diagnosis, prognosis, and therapy. Arch Dermatol 1998;134:1137-41.
8. Laffitte E, Borradori L. Bullous pemphigoid and related disorders. In: Herd M editor. Autoimmune diseases of the skin. Wien-New York: Springer Verlag; 2001. p. 63-83.
9. Rzany B, Weller N. Epidemiology of autoimmune skin disorders. In: Hertl M editor. Autoimmune diseases of the skin. Wien-New York: Springer Verlag; 2001. p. 21-38.
10. Castanet J, Lacour JP, Ortonne JP. Atypical clinical forms of bullous pemphigoid. Ann Dermatol Venereol 1990;117:73-82.
11. Salomon RJ, Briggaman RA, Wernikoff SY, Kayne AL. Localized bullous pemphigoid. A mimic of acute contact dermatitis. Arch Dermatol 1987;123:389-92.
12. Callens A, Vaillant L, Machet MC, Arbeille B, Machet L, De Muret A et al. Localized atypical pemphigoid on lymphoedema following radiotherapy. Acta Derm Venereol 1993;73:461-4.
13. Ernst TM, Marsch WC. Develop of localized pemphigoid following radiation treatment. Dermatologica 1982;164:73-81.
14. Borradori L, Prost C, Wolkenstein P, Bernard P, Baccard M, Morel P. Localized pretibial pemphigoid and pemphigoid nodularis. J Am Acad Dermatol 1992;27:863-7.
15. Person JR. Hydrostatic bullae and pretibial pemphigoid. Int J Dermatol 1983; 22:237-8.
16. Nunzi E, Rongioletti F, Parodi A, Rebora A. Dyshidrosiform pemphigoid. J Am Acad Dermatol 1988;19:568-9.
17. Descamps V, Flageul B, Vignon-Pennamen D, Prigent F, Martinet C, Cottenot F et al. Dyshidrosiform pemphigoid: report of three cases. J Am Acad Dermatol 1992;26:651-2.
18. Farrell AM, Kirtschig G, Dalziel KL, Allen J, Dootson G, Edwards S et al. Childhood vulval pemphigoid: a clinical and immunopathological study of five patients. Br J Dermatol 1999;140:308-12.
19. Bean SF, Michel B, Furey N, Thorne G, Meltzer L. Vesicular pem-phigoid. Arch Dermatol 1976;112:1402-4.
20. Ohnishi Y, Tajima S, Ishibashi A, Fujiwara S. A vesicular bullous pemphigoid with an autoantibody against plectin. Br J Dermatol 2000;142:813-5.
21. Komine M, Nashiro K, Asahina A, Matsuyama T, Furue M, Tsuchida T et al. Vesicular pemphigoid. Int J Dermatol 1992;31:868-70.
22. Ueda Y, Nashiro K, Seki Y, Otsuka F, Tamaki K, Ishibashi Y. Pemphigoid vegetans. Br J Dermatol 1989;120:449-53.
23. Poulain JF, Carmi E, Thelu F, Lok C, Denoeux JP. Pigmented pemphigoid. Ann Dermatol Venereol 1999;126:616-8.
24. Cliff S, Holden CA. Pemphigoid nodularis: a report of three cases and review of the literature. Br J Dermatol 1997;136:398-401.
25. Gengoux P, Lachapelle JM. Pemphigoid presenting as atypical excoriated prurigo: regarding 11 cases. Dermatology 1997;194:392-4.
26. Korman NJ, Woods SG. Erythrodermic bullous pemphigoid is a clinical variant of bullous pemphigoid. Br J Dermatol 1995;133:967-71.
27. Alonso-Llamazares J, Dietrich SM, Gibson LE. Bullous pemphigoid presenting as exfoliative erythroderma. J Am Acad Dermatol 1998;39:827-30.
28. Cordel N, Courville P, Martel P, Musette P, Joly P. Extensive erosive bullous pemphigoid: an atypical and serious clinical variant. Br J Dermatol 2002;146:537-9.
29. Kirtschig G, Chow ET, Venning VA, Wojnarowska FT. Acquired subepidermal bullous diseases associated with psoriasis: a clinical, immunopathological and immunogenetic study. Br J Dermatol 1996;135:738-45.
30. Saeki H, Hayashi N, Komine M, Soma Y, Shimada S, Watanabe K et al. A case of generalized pustular psoriasis followed by bullous disease: anatypical case of bullous pemphigoid or a novel bullous disease? Br J Dermatol 1996;134:152-5.
31. Sobel S, Miller R, Shatin H. Lichen planus pemphigoides, immunofluorescence findings. Arch Dermatol 1976;112:1280-3.
32. Stingl G, Hollubar K. Coexistence of lichen planus and bullous pemphigoid. An immunopathological study. Br J Dermatol 1975;93:313-20.
33. Trueb RM, Didierjean L, Fellas A, Elias A, Borradori L. Childhood bullous pemphigoid. Report of a case with characterization of the targeted antigens. J Am Acad Dermatol 1999;40:338-44.
34. Taylor G, Venning V, Wojnarowska F, Welch K. Bullous pemphigoid and autoimmunity. J Am Acad Dermatol 1993;29:181-4.
35. Chan LS, Vanderlugt CJ, Hashimoto T, Nishikawa T, Zone JJ, Black MM et al. Epitope spreading: lessons from autoimmune skin diseases. J Invest Dermatol 1998;110:103-9.
36. Chosidow O, Doppler V, Bensimon G, Joly P, Salachas F, Lacomblez L et al. Bullous pemphigoid and amyotrophic lateral sclerosis: a new clue for understanding the bullous disease. Arch Dermatol 2000;136:521-4.
37. Laffitte E, Burkhard PR, Fontao L, Jaunin F, Saurat JH, Chofflon M et al. Bullous pemphigoid antigen 1 isoform s: potential new target auto-antigens in multiple sclerosis? Br J Dermatol 2005;152:537-40.
38. Vassileva S. Drug-induced pemphigoid: bullous and cicatricial. Clin Dermatol 1998;16:379-87.
39. Bastuji-Garin S, Joly P, Picard-Dahan C, Bernard P, Vaillant L, Pauwels C et al. Drugs associated with bullous pemphigoid. A case-control study. Arch Dermatol 1996;132:272-6.
40. Labib RS, Anhalt GJ, Patel HP, Mulasim DF, Diaz LA. Molecular heterogeneity of the bullous pemphigoid antigens as detected by immunoblotting. J Immunol 1986;136:1231-5.
41. Borradori L, Sonnenberg A. Structure and function of hemidesmosomes: more than simple adhesion complexes. J Invest Dermatol 1999;112:411-8.
42. Zillikens D, Rose PA, Balding SD, Liu Z, Olague-Marchan M, Diaz LA et al. Tight clustering of extracellular BP180 epitopes recognized by bullous pemphigoid autoantibodies. J Invest Dermatol 1997;109:573-9.
43. Zillikens D, Mascaro JM, Rose PA, Liu Z, Ewing SM, Caux F et al. A highly sensitive enzyme-linked immunosorbent assay for the detection of circulating autoantibodies in patients with bullous pemphigoid. J Invest Dermatol 1997;109:679-83.
44. Haase C, Budinger L, Borradori L, Yee C, Merk HF, Yancey K et al. Detection of IgG autoantibodies in the sera of patients with bullous and gestational pemphigoid: ELISA studies utilizing a baculovirus-encoded form of bullous pemphigoid antigen 2. J Invest Dermatol 1998;110:282-6.
45. Perriard J, Jaunin F, Favre B, Budinger L, Hertl M, Saurat JH et al. IgG autoantibodies from bullous pemphigoid (BP) patients bind antigenic sites on both the extracellular and the intracellular domains of the BP antigen 180. J Invest Dermatol 1999;112:141-7.
46. Di Zenzo G, Grosso F, Terracina M, Mariotti F, De Pita O, Owaribe K et al. Characterization of the anti-BP180 autoantibody reactivity profile and epitope mapping in bullous pemphigoid patients. J Invest Dermatol 2004;122:103-10.
47. Tanaka M, Hashimoto T, Amagai M, Shimizu N, Ikeguchi N, Tsubata T et al. Characterization of bullous pemphigoid antibodies by use of recombinant bullous pemphigoid antigen proteins. J Invest Dermatol 2001;97:725-8.
48. Skaria M, Jaunin F, Hunziker T, Riou S, Schumann H, Bruckner-Tuderman L et al. IgG autoantibodies from bullous pemphigoid patients recognize multiple antigenic reactive sites located predominantly within the B and C subdomain of the COOH-terminus of BP230. J Invest Dermatol 2000;114:998-1004.
49. Hall RP 3rd, Murray JC, McCord MM, Rico MJ, Streilein RD. Rabbits immunized with a peptide encoded for by the 230-kd bullous pemphigoid antigen cDNA develop an enhanced inflammatory response to UVB irradiation: a potential animal model for bullous pemphigoid. J Invest Dermatol 1993;101:9-14.
50. Liu Z, Shapiro SD, Zhou X, Twining SS, Senior RM, Giudice GJ et al. A critical role for neutrophil elastase in experimental bullous pemphigoid. J Clin Invest 2000;105:113-23.
51. Liu Z, Li N, Diaz LA, Shipley M, Senior RM, Werb Z. Synergy between a plasminogen cascade and MMP-9 in autoimmune disease. J Clin Invest 2005;115:879-87.
52. Shimanovich I, Mihai S, Oostingh GJ, Ilenchuk TT, Brocker EB, Opdenakker G et al. Granulocyte-derived elastase and gelatinase B are required for dermal-epidermal separation induced by autoantibodies from patients with epidermolysis bullosa acquisita and bullous pemphigoid. J Pathol 2004;204:519-27.
53. Delgado JC, Turbay D, Yunis EJ, Yunis JJ, Morton ED, Bhol K et al. A common major histocompatibility complex class II allele HLA-DQB1*0301 is present in clinical variants of pemphigoid. Proc Natl Acad Sci 1996;93:8569-71.
54. Zenzo G, Calabresi V, Olasz EB, Yancey KB, Zambruno G. Intramolecular epitope spreading against BPAG2 during the humoral response of mice grafted with human BPAG2 (hBP AG2) Transgenic skin. J Invest Dermatol 2005;124:A12.
55. Di Zenzo G, Thoma-Uszynski S, Fontao L, Calabresi V, Hofmann S, Lacour J-P et al. Multicenter prospective study of the humoral autoimmune in a large cohort of bullous pemphigoid patients. J Invest Dermatol 2006;126:s22.
56. Verraes S, Hornebeck W, Polette M, Borradori L, Bernard P. Respective contribution of neutrophil elastase and matrix metalloproteinase 9 in the degradation of BP180 (type XVII collagen) in human bullous pemphigoid. J Invest Dermatol 2001;117:1091-6.
57. Shimanovich I, Mihai S, Oostingh GJ, Denchuk TT, Brocker EB, Opdenakker G et al. Granulocyte-derived elastase and gelatinase B are required for dermal-epidermal separation induced by autoantibodies from patients with epidermolysis bullosa acquisita and bullous pemphigoid. J Pathol 2004;204:519-27.
58. Schmidt E, Reimer S, Kruse N, Jainta S, Brocker EB, Marinkovich MP et al. Autoantibodies to BP180 associated with bullous pemphigoid release interleukin-6 and interleukin-8 from cultured human keratinocytes. J Invest Dermatol 2000;115:842-8.
59. Budinger L, Borradori L, Yee C, Eming R, Ferencik S, Grosse-Wilde H et al. Identification and characterization of autoreactive T cell responses to bullous pemphigoid antigen 2 in patients and healthy controls. J Clin Invest 1998;102:2082-9.
60. Thoma-Uszynski S, Uter W, Schwietzke S, Schuler G, Borradori L, Hertl M. Autoreactive T and B cells from bullous pemphigoid (BP) patients recognize epitopes clustered in distinct regions of BP180 and BP230. J Immunol 2006;176:2015-23.
61. Vaillant L, Bernard P, Joly P, Prost C, Labeille B, Bedane C et al. Evaluation of clinical criteria for diagnosis of bullous pemphigoid. French bullous study group. Arch Dermatol 1998;134:1075-80.
62. Joly P, Courville P, Lok C, Bernard P, Saiag P, Dreno B et al.; French Bullous Study Group. Clinical criteria for the diagnosis of bullous pemphigoid: a reevaluation according to immunoblot analysis of patient sera. Dermatology 2004;208:16-20.
63. Rieckhoff-Cantoni L, Bernard P, Didierjean L, Imhof K, Kinloch-de Loes S, Saurat JH. Frequency of bullous pemphigoid-like antibodies as detected by Western immunoblot analysis in pruritic dermatoses. Arch Dermatol 1992;128:791-4.
64. Hachisuka H, Kurose K, Karashima T, Mori O, Maeyama Y. Serum from elderly individuals contains anti-basement membrane zone antibodies. Arch Dermatol 1996;132:1201-5.
65. Gammon WR, Kowalewski C, Chorzelski TP, Kumar V, Briggaman RA, Beutner EH. Direct immunofluorescence studies of sodium chloride-separated skin in the differential diagnosis of bullous pemphigoid and epidermolysis bullosa acquisita. J Am Acad Dermatol 1990;22:664-70.
66. De Jong MC, Bruins S, Heeres K, Jonkman MF, Nieboer C, Boorsma DM et al. Bullous pemphigoid and epidermolysis bullosa acquisita. Differentiation by fluorescence overlay antigen mapping. Arch Dermatol 1996;132:151-7.
67. Vodegel RM, Jonkman MF, Pas HH, de Jong MC. U-serrated immunodeposition pattern differentiates type VII collagen targeting bullous diseases from other subepidermal bullous autoimmune diseases. Br J Dermatol 2004;151:112-8.
68. Vodegel RM, De Jong MC, Meijer HJ, Weytingh MB, Pas HH, Jonkman MF. Enhanced diagnostic immunofluorescence using biopsies transported in saline. BMC Dermatol 2004;4:10.
69. Gammon WR, Fine JD, Forbes M, Briggaman RA. Immunofluorescence on split skin for the detection and differentiation of basement membrane zone autoantibodies. J Am Acad Dermatol 1992;27:79-87.
70. Ishiko A, Shimizu H, Kikuchi A, Ebihara T, Hashimoto T, Nishikawa T. Human autoantibodies against the 230-kD bullous pemphigoid antigen (BPAG1) bind only to the intracellular domain of the hemidesmosome, whereas those against the 180-kD bullous pemphigoid antigen (BPAG2) bind along the plasma membrane of the hemidesmosome in normal human and swine skin. J Clin Invest 1993;91:1608-15.
71. Christophoridis S, Büdinger L, Borradori L, Hunziker T, Merk HF, Hertl M. IgG, IgA and IgE antibodies against the ectodomain of BP180 in patients with bullous and cicatricial pemphigoid and linear IgA bullous dermatosis. Br J Dermatol 2000;143:349-55.
72. Laffitte E, Shafaatian R, Fontao L, Favre B, Koster J, Saurat JH et al. Production of the bullous pemphigoid antigen 230 (BP230) by Saccharomyces cerevisiae and Pichia pastoris. Prot Expr Purif 2003;29:141-7.
73. Schmidt E, Obe K, Brocker EB, Zillikens D. Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. Arch Dermatol 2000;136:174-8.
74. Hofmann S, Thoma-Uszynski S, Hunziker T, Bernard P, Koebnick C, Stauber A et al. Severity and phenotype of bullous pemphigoid relate to autoantibody profile against the NH2- and COOH-terminal regions of the BP180 ectodomain. J Invest Dermatol 2002;119:1065-73.
75. Thoma-Uszynski S, Uter W, Schwietzke S, Hofmann SC, Hunziker T, Bernard P et al. BP230- and BP180-specific auto-antibodies in bullous pemphigoid. J Invest Dermatol 2004;122:1413-22.
76. Korman NJ. Bullous pemphigoid. J Am Acad Dermatol 1987;16:907-24.
77. Roujeau JC, Lok C, Bastuji-Garin S, Mhalla S, Enginger V, Bernard P. High risk of death in elderly patients with extensive bullous pemphigoid. Arch Dermatol 1998;134:465-9.
78. Joly P, Benichou J, Lok C, Hellot MF, Saiag P, Tancrede-Bohin E et al. Prediction of survival for patients with bullous pemphigoid: a prospective study. Arch Dermatol 2005;141:691-8.
79. Bystryn JC, Rudolph JL. Why is the mortality of bullous pemphigoid greater in Europe than in the US? J Invest Dermatol 2005;124:xx-xxi.
80. Korman NJ. New and emerging therapies in the treatment of blistering diseases. Dermatol Clin 2000;18:127-37.
81. Joly P, Roujeau JC, Benichou J, Picard C, Dreno B, Delaporte E et al.; Bullous Diseases French Study Group. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl Med 2002; 346:321-7.
82. Morel P, Guillaume JC. Treatment of bullous pemphigoid with prednisolone only: 0.75 mg/kg/day versus 1.25 mg/kg/day. A multicenter randomized study. Ann Dermatol Venereol 1984;111:925-8.
83. Roujeau JC, Guillaume JC, Morel P, Crickx B, Dalle E, Doutre MS et al. Plasma exchange in bullous pemphigoid. Lancet 1984;2:486-8.
84. Dreno B, Sassolas B, Lacour P, Montpoint S, Lota I, Giordano F et al. Methylprednisolone versus prednisolone methylsulfobenzoate in pemphigoid: a comparative multicenter study. Ann Dermatol Venereol 1993;120:518-21.
85. Guillaume JC, Vaillant L, Bernard P, Picard C, Prost C, Labeille B et al. Controlled trial of azathioprine and plasma exchange in addition to prednisolone in the treatment of bullous pemphigoid. Arch Dermatol 1993;129:49-53.
86. Guillot B, Donadio D, Guilhou JJ, Meynadier J. Long term plasma exchange therapy in bullous pemphigoid. Acta Derm Venereol 1986;66:73-5.
87. Fivenson DP, Breneman DL, Rosen GB, Hersh CS, Cardone S, Mutasim D. Nicotinamide and tetracycline therapy of bullous pemphigoid. Arch Dermatol 1994;130:753-8.